Ro Stock
| Valuation | $7B1 |
| Valuation Date | Feb 15, 2022 |
| Implied Valuation | n/a |
| Last Price | $5.27 |
| 52-Week High | $5.89 |
| 52-Week Low | $3.24 |
| YTD Return | +36.53% |
| 1-Year Return | +29.48% |
| 3-Year Return | n/a |
| Total Funding | $1.03B2, 3 |
| Latest Round Amount | $150M1 |
| Latest Round | Series D-1 |
| Funding Rounds | 6 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Ro
Ro is a direct-to-consumer telehealth company that diagnoses patients online, prescribes treatment and delivers medication to their door. It operates a vertically integrated platform that combines a nationwide network of licensed providers with its own pharmacies and at-home diagnostics. Its services cover areas like weight loss, sexual health, hair loss, fertility and skincare. Ro makes money by selling prescription medications and treatment subscriptions directly to patients, who pay cash prices without going through insurance.
Invest in Ro
Ro is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Hiive.
Hiive is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on HiiveStock Analysis may be compensated for user sign-ups through Hiive links. Hiive is not affiliated with Stock Analysis. Securities offered by Hiive Markets Limited, member of FINRA/SIPC.
News
Ro Offers Eli Lilly's Foundayo Oral GLP-1
Ro added Eli Lilly's Foundayo (orforglipron), a once-daily oral GLP-1 for obesity, to its weight loss formulary with cash-pay pricing starting at $149 per month for the lowest dose.
Ro Offers Eli Lilly's Foundayo, the Newest GLP-1 Innovation
Ro began offering Eli Lilly's oral GLP-1 Foundayo (orforglipron) through its telehealth platform, expanding its weight-management formulary to include the newest branded GLP-1 option.
Ro Offers Eli Lilly's Foundayo™, the Newest GLP-1 Innovation
Ro added Eli Lilly's once-daily oral GLP-1 Foundayo to its weight-loss formulary, with cash-pay pricing starting at $149 per month for the lowest dose.
Ro Launches Eli Lilly's KwikPen, Offering Patients a More Convenient Way to Take Zepbound
Ro began offering Eli Lilly's Zepbound KwikPen nationwide with transparent cash-pay pricing starting at $299 per month for the starter dose.
Ro Launches Eli Lilly's KwikPen®, Offering Patients a More Convenient Way to Take Zepbound®
Ro began offering Eli Lilly's FDA-approved Zepbound KwikPen nationwide on its platform, with cash-pay monthly pricing starting at $299 for the 2.5 mg starter dose.
Ro Helps Patients Save Up to $1,200 Per Year on Wegovy Through Collaboration with Novo Nordisk
Ro introduced prepaid Wegovy pen and pill plans with Novo Nordisk that can save cash-pay patients up to $1,200 per year on the GLP-1 treatment.
Ro Uses Super Bowl Debut to Reframe GLP-1s as Clinical Care
Ro's Healthier on Ro Super Bowl campaign highlights lab and health metrics rather than cosmetic weight-loss messaging. Co-founder Saman Rahmanian said the ad builds on Williams' 2025 partnership to co...
Ro CEO wants to erase GLP-1 stigma with first Super Bowl ad featuring Serena Williams
Ro CEO Zachariah Reitano discussed the company's Super Bowl debut and its push to normalize GLP-1 treatment through Serena Williams' patient story and a national advertising campaign.
Ro Debuts First Super Bowl Ad Starring Serena Williams
Ro aired its first Super Bowl commercial during Super Bowl LX to launch the Healthier on Ro campaign, featuring GLP-1 patient ambassador Serena Williams. CEO Zach Reitano said the ad aims to show GLP-...
Serena Williams Stars in Ro Super Bowl Commercial for GLP-1s
Ro's Super Bowl spot features Serena Williams discussing weight loss, joint stress, blood sugar, and cholesterol improvements she attributes to GLP-1 treatment on Ro. The campaign is part of Ro's push...
Ro Debuts First-Ever Super Bowl Commercial Starring Serena Williams
Ro launched its first Super Bowl commercial starring Serena Williams as part of a national "Healthier on Ro" campaign highlighting GLP-1 weight-loss treatment and broader health benefits.
Ro partners with Amgen to study barriers to obesity care, GLP-1 access
U.S. telehealth firm Ro said on Tuesday it has entered a research collaboration with drugmaker Amgen to examine challenges patients and providers face in accessing obesity treatments, including GLP-1 ...
Ro Launches Wegovy® Pill Through Integration with Novo Nordisk
Ro integrated with Novo Nordisk to offer the new oral Wegovy pill on day one of its nationwide launch, giving patients access at the lowest available cash-pay price.
Novo Nordisk opens weight loss drug Wegovy to Hims & Hers, Ro and Life MD telehealth
Novo Nordisk said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and Life MD. The Danish drugmaker is racing to capture more patients now that many comp...
Telehealth firm Ro to provide single-dose vials of Lilly's Zepbound to obesity patients
Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound to patients with obesity.
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
Direct-to-consumer health-care startup Ro said its platform will now offer more affordable single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lilly. Ro will offer a ...
Gelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million
BOSTON--(BUSINESS WIRE)--Gelesis announced today that Ro, a leading and rapidly growing U.S. direct-to-patient healthcare company, has placed a $15 million pre-paid order for the company's commercial ...
PureTech Founded Entity Gelesis Receives $30 Million Plenity® Order from Ro
BOSTON--(BUSINESS WIRE)--PureTech announces that its Founded Entity, Gelesis, received a $30 million fully paid pre-order for Plenity® from Ro.
Gelesis Receives $30 Million Plenity Order from Ro
BOSTON--(BUSINESS WIRE)--Gelesis announced today that leading U.S. direct-to-patient healthcare company Ro has placed a $30 million fully paid pre-order for the company's first commercial product for ...
ChromaDex and Ro Partner for New Product Development
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #collaboration--ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology comp...